<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792739</url>
  </required_header>
  <id_info>
    <org_study_id>ICU_probiotics</org_study_id>
    <nct_id>NCT01792739</nct_id>
  </id_info>
  <brief_title>Lactobacillus Preparation on the Incidence of Diarrhea</brief_title>
  <official_title>The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to clarify the impact of lactobacillus preparation on the
      incidence of diarrhea in ICU-admitted patients.

      Almost all patients in ICU are treated with antibiotics for the effective control of various
      infections. However, antibiotics-associated diarrhea is another matter of concern. Many
      previous studies were proved that the use of probiotic lactobacillus preparation can reduce
      antibiotics-associated diarrhea in ward-admitted patients. In this study, we are planning to
      perform a similar study in severely ill patients in ICU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Diarrhea-free days</measure>
    <time_frame>Duration from the first-administration day of probiotics till the first onset day of diarrhea during ICU residence (up to 8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>If patients admit to ICU, the patient can be registered to probiotics or placebo arm. After the registration, probiotics would be administered to the patients. If loose stool &gt;600ml/day occurs during ICU residence, we can determine that occurence of diarrhea.
&quot;Diarrhea-free days&quot; mean the duration from the day of 1st administration of probiotics till the day of 1st diarrhea.
If patients are transferred to ward, this study ends in each patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28day-mortality</measure>
    <time_frame>28 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mortality in 28th day of ICU residence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive results of C.difficile toxin</measure>
    <time_frame>The first onset of diarrhea during ICU residence (up to 8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>If diarrhea (&gt;600ml/day) occurs during ICU residence, we will perform C.difficile toxin assays to determine the cause of diarrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-acquired pneumonia</measure>
    <time_frame>The first day of occurence of ICU-acquired pneumonia (up to 8 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Definition of ICU-acquired pneumonia
Newly developed pneumonia during ICU residence
Aggravation of pneumonia during ICU residence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Diarrhea</condition>
  <condition>Death</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Kadit B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic Lactobacillus casei variety rhamnosus granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kadit A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus casei variety rhamnosus granules</intervention_name>
    <description>Lactobacillus casei variety rhamnosus granules
: 3 gram per day (1g-1g-1g, 3 times per day)</description>
    <arm_group_label>Kadit B</arm_group_label>
    <other_name>RAMNOS GRANULS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo granules
: 3 gram per day (1g-1g-1g, 3 times per day)</description>
    <arm_group_label>Kadit A</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted in intensive care unit

          -  Age more than 19

        Exclusion Criteria:

          -  Diarrhea occurence within 1 week of ICU admission

          -  Recent history of probiotics use (within 1 month)

          -  GI obstruction

          -  History of abnormal symptoms and sign for the probiotics use (rash, edema, sepsis,
             etc.)

          -  immunocompromized patients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Hoon Lee, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Hoon Lee, Doctor</last_name>
    <phone>82 10 9563 2310</phone>
    <email>kauri670@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joo-Won Min, M.S</last_name>
    <phone>82 10 3321 7199</phone>
    <email>kmfindie@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Bundang-Gu</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Sun Park, M.S</last_name>
      <phone>82 10 3297 4632</phone>
      <email>jspark.im@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Deokyang-gu</state>
        <zip>412-270</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Won Min, M.S</last_name>
      <phone>82-31-810-5423</phone>
      <email>kmfindie@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongjak-gu</state>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Hoon Lee, Doctor</last_name>
      <phone>82-10-9563-2310</phone>
      <email>kauri670@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007 Jul 14;335(7610):80. Epub 2007 Jun 29.</citation>
    <PMID>17604300</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 13, 2013</lastchanged_date>
  <firstreceived_date>February 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Chang-Hoon Lee</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Intentive care units</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
